Magnetic Fields in the Milky Way

This chapter presents a review of observational studies to determine the magnetic field in the Milky Way, both in the disk and in the halo, focused on recent developments and on magnetic fields in the diffuse interstellar medium. I discuss some terminology which is confusingly or inconsistently used and try to summarize current status of our knowledge on magnetic field configurations and strengths in the Milky Way. Although many open questions still exist, more and more conclusions can be drawn on the large-scale and small-scale components of the Galactic magnetic field. The chapter is concluded with a brief outlook to observational projects in the near future.Comment: 22 pages, 5 figures, to appear in "Magnetic Fields in Diffuse Media", eds. E.M. de Gouveia Dal Pino and A. Lazaria

Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus:DUALING Prospective Nationwide Matched Cohort Study

Background. Confirming the efficacy of dolutegravir/lamivudine in clinical practice solidifies recommendations on its use. Methods. Prospective cohort study (DUALING) in 24 human immunodeficiency virus (HIV) treatment centers in the Netherlands. HIV RNA–suppressed cases were on triple-drug antiretroviral regimens without prior virological failure or resistance and started dolutegravir/lamivudine. Cases were 1:2 matched to controls on triple-drug antiretroviral regimens by the use of dolutegravir-based regimens, age, sex, transmission route, CD4+ T-cell nadir, and HIV RNA zenith. The primary endpoint was the treatment failure rate in cases versus controls at 1 year by intention-to-treat and on-treatment analyses with 5% noninferiority margin. Results. The 2040 participants were 680 cases and 1380 controls. Treatment failure in the 390 dolutegravir-based cases versus controls occurred in 8.72% and 12.50% (difference: −3.78% [95% confidence interval {CI}, −7.49% to .08%]) by intention-to-treat and 1.39% and 0.80% (difference: 0.59% [95% CI, –.80% to 1.98%]) by on-treatment analyses. The treatment failure risk in 290 non-dolutegravir-based cases was also noninferior to controls. Antiretroviral regimen modifications unrelated to virological failure explained the higher treatment failure rate by intention-to-treat. A shorter time on triple-drug antiretroviral therapy and being of non-Western origin was associated with treatment failure. Treatment failure, defined as 2 consecutive HIV RNA &gt;50 copies/mL, occurred in 4 cases and 5 controls but without genotypic resistance detected. Viral blips occured comparable in cases and controls but cases gained more weight, especially when tenofovir-based regimens were discontinued. Conclusions. In routine care, dolutegravir/lamivudine was noninferior to continuing triple-drug antiretroviral regimens after 1 year, supporting the use of dolutegravir/lamivudine in clinical practice.</p

Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus:DUALING Prospective Nationwide Matched Cohort Study

Background. Confirming the efficacy of dolutegravir/lamivudine in clinical practice solidifies recommendations on its use. Methods. Prospective cohort study (DUALING) in 24 human immunodeficiency virus (HIV) treatment centers in the Netherlands. HIV RNA–suppressed cases were on triple-drug antiretroviral regimens without prior virological failure or resistance and started dolutegravir/lamivudine. Cases were 1:2 matched to controls on triple-drug antiretroviral regimens by the use of dolutegravir-based regimens, age, sex, transmission route, CD4+ T-cell nadir, and HIV RNA zenith. The primary endpoint was the treatment failure rate in cases versus controls at 1 year by intention-to-treat and on-treatment analyses with 5% noninferiority margin. Results. The 2040 participants were 680 cases and 1380 controls. Treatment failure in the 390 dolutegravir-based cases versus controls occurred in 8.72% and 12.50% (difference: −3.78% [95% confidence interval {CI}, −7.49% to .08%]) by intention-to-treat and 1.39% and 0.80% (difference: 0.59% [95% CI, –.80% to 1.98%]) by on-treatment analyses. The treatment failure risk in 290 non-dolutegravir-based cases was also noninferior to controls. Antiretroviral regimen modifications unrelated to virological failure explained the higher treatment failure rate by intention-to-treat. A shorter time on triple-drug antiretroviral therapy and being of non-Western origin was associated with treatment failure. Treatment failure, defined as 2 consecutive HIV RNA &gt;50 copies/mL, occurred in 4 cases and 5 controls but without genotypic resistance detected. Viral blips occured comparable in cases and controls but cases gained more weight, especially when tenofovir-based regimens were discontinued. Conclusions. In routine care, dolutegravir/lamivudine was noninferior to continuing triple-drug antiretroviral regimens after 1 year, supporting the use of dolutegravir/lamivudine in clinical practice.</p

Constraining landscape history and glacial erosivity using paired cosmogenic nuclides in Upernavik, northwest Greenland

High-latitude landscape evolution processes have the potential to preserve old, relict surfaces through burial by cold-based, nonerosive glacial ice. To investigate landscape history and age in the high Arctic, we analyzed in situ cosmogenic 10Be and 26Al in 33 rocks from Upernavik, northwest Greenland. We sampled adjacent bedrock-boulder pairs along a 100 km transect at elevations up to 1000 m above sea level. Bedrock samples gave signifi cantly older apparent exposure ages than corresponding boulder samples, and minimum limiting ages increased with elevation. Two-isotope calculations (26Al/10Be) on 20 of the 33 samples yielded minimum limiting exposure durations up to 112 k.y., minimum limiting burial durations up to 900 k.y., and minimum limiting total histories up to 990 k.y. The prevalence of 10Be and 26Al inherited from previous periods of exposure, especially in bedrock samples at high elevation, indicates that these areas record long and complex surface exposure histories, including signifi cant periods of burial with little subglacial erosion. The long total histories suggest that these highelevation surfaces were largely preserved beneath cold-based, nonerosive ice or snowfi elds for at least the latter half of the Quaternary. Because of high concentrations of inherited nuclides, only the six youngest boulder samples appear to record the timing of ice retreat. These six samples suggest deglaciation of the Upernavik coast at 11.3 ± 0.5 ka (average ± 1 standard deviation). There is no difference in deglaciation age along the 100 km sample transect, indicating that the ice-marginal position retreated rapidly at rates of ~120 m yr−1

Grondgedachten: over grond en ruimtegebruik

Item does not contain fulltext125 p

Paired bedrock and boulder 10Be concentrations resulting from early Holocene ice retreat near Jakobshavn Isfjord, western Greenland

We measured in situ cosmogenic 10Be in 16 bedrock and 14 boulder samples collected along a 40-km transect outside of and normal to the modern ice margin near Sikuijuitsoq Fjord in central-west Greenland (69°N). We use these data to understand better the efficiency of glacial erosion and to infer the timing, pattern, and rate of ice loss after the last glaciation. In general, the ages of paired bedrock and boulder samples are in close agreement (r2 = 0.72). Eleven of the fourteen paired bedrock and boulder samples are indistinguishable at 1σ; this concordance indicates that subglacial erosion rates are sufficient to remove most or all 10Be accumulated during previous periods of exposure, and that few, if any, nuclides are inherited from pre-Holocene interglaciations. The new data agree well with previously-published landscape chronologies from this area, and suggest that two chronologically-distinct land surfaces exist: one outside the Fjord Stade moraine complex (∼10.3 ± 0.4 ka; n = 7) and another inside (∼8.0 ± 0.7 ka; n = 21). Six 10Be ages from directly outside the historic (Little Ice Age) moraine show that the ice margin first reached its present-day position ∼7.6 ± 0.4 ka. Early Holocene ice margin retreat rates after the deposition of the Fjord Stade moraine complex were ∼100–110 m yr−1. Sikuijuitsoq Fjord is a tributary to the much larger Jakobshavn Isfjord and the deglaciation chronologies of these two fjords are similar. This synchronicity suggests that the ice stream in Jakobshavn Isfjord set the timing and pace of early Holocene deglaciation of the surrounding ice margin

COVID-19 epidemiology and performance of the WHO clinical algorithm to diagnose COVID-19 in people with HIV from Ukraine

Background: The two main objectives were to evaluate the COVID-19 point prevalence and the test performance of the WHO case definition to diagnose COVID-19 clinically in people with HIV in West Ukraine.Methods: Multicenter cross-sectional study in Lviv, Ukraine, from October 2020-November 2021. COVID-19 unvaccinated people with HIV were included regardless of COVID-19 symptoms at routine clinical visits and had standardized medical, quality of life (EQ(5D)) and SARS-CoV-2 serology assessments. Reported symptoms indicating potential COVID-19 events at inclusion or between March 2020 and inclusion were classified by the WHO case definition as suspected, probable or confirmed. A clinical COVID-19 case was defined as being SARS-CoV-2 seropositive with at least a suspected COVID-19 according to the WHO case definition. The primary endpoints were the clinical COVID-19 prevalence and the test characteristics of the WHO case definition with SARS-CoV-2 serology as reference. (Clinicaltrials.gov:NCT04711954).Results: The 971 included people with HIV were median 40 years, 38.8% women, 44.8% had prior AIDS, and 55.6% had comorbidities. SARS-CoV-2 seroprevalence was 40.1% (95%CI:37.0–43.1) and 20.5% (95%CI:18.0–23.1) had clinical COVID-19 median 4 months (IQR:2–7) before inclusion. Clinical COVID-19 occurred less frequently in people with HIV with tuberculosis history, injecting drug use, CD4+ T-cells &lt;200/mL and unemployment. The quality of life was not impacted after COVID-19. An at least probable COVID-19 classification by the WHO case definition had 44.1% sensitivity (95%CI:38.7–49.7), 85.2% specificity (95%CI:81.5–88.4), 66.6% positive predictive value (95%CI:59.8–73.0) and 69.5% negative predictive value (95%CI:65.5–73.3) to diagnose COVID-19.Conclusions: COVID-19 unvaccinated people with HIV from Ukraine had a significant COVID-19 rate and using the WHO case definition had insufficient diagnostic accuracy to diagnose these cases. The lower burden in vulnerable people with HIV was unexpected but might reflect a shielding effect.</p